This is a non-steroidal anti-inflammatory drug (diclofenac 4% gel). It is used to treat actinic keratose.
It is used over a 3-6 month period and aims to alleviate the lesions without the local reactions seen with all other topical agents.
The studies were all performed on European skin and were shown to be quite positive.
However, Solaraze has “flopped” when treating the significant lesions seen in Australian skin.
Only occasional patients in Australia have benefited and so Solaraze is infrequently recommended as a treatment.